NCT03314935 A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors Status COMPLETED Phase PHASE1/PHASE2
NCT03313778 Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT03313557 AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies Status COMPLETED Phase PHASE1
NCT03301896 Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies Status TERMINATED Phase PHASE1
NCT03264066 A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors Status COMPLETED Phase PHASE2
NCT03258515 A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers Status COMPLETED Phase PHASE1
NCT03258151 Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients Status UNKNOWN Phase N/A
NCT03255070 A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01) Status COMPLETED Phase PHASE1
NCT03252938 Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT03235570 A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102) Status COMPLETED Phase PHASE1
NCT03175224 APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Status RECRUITING Phase PHASE2
NCT03144661 An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies Status TERMINATED Phase PHASE1
NCT03101488 Phase I Study of KN035 in Chinese Subjects With Advanced Solid Tumors Status COMPLETED Phase PHASE1
NCT03065062 Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors Status SUSPENDED Phase PHASE1
NCT03030417 Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas Status COMPLETED Phase PHASE1
NCT03010176 Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001) Status COMPLETED Phase PHASE1
NCT03006887 Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors Status COMPLETED Phase PHASE1